Dr John Heymach and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of PD-1 immunotherapy versus chemo alone as first line lung cancer treatment.

For more on these results, watch Dr Lopes present the data in the press conference, watch his interview with ecancer and read our news coverage here.